Breast Cancer - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Breast Cancer - Pipeline Review, H1 2015’, provides an overview of the Breast Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
Introduction 16
Breast Cancer Overview 17
Therapeutics Development 18
Breast Cancer - Therapeutics under Development by Companies 20
Breast Cancer - Therapeutics under Investigation by Universities/Institutes 51
Breast Cancer - Pipeline Products Glance 60
Breast Cancer - Products under Development by Companies 64
Breast Cancer - Products under Investigation by Universities/Institutes 111
Breast Cancer - Companies Involved in Therapeutics Development 122
Breast Cancer - Therapeutics Assessment 468
Drug Profiles 510
Breast Cancer - Recent Pipeline Updates 1716
Breast Cancer - Dormant Projects 2169
Breast Cancer - Discontinued Products 2208
Breast Cancer - Product Development Milestones 2219
Appendix 2231
List Of Tables
List of Tables
Number of Products under Development for Breast Cancer, H1 2015 103
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015 104
Number of Products under Development by Companies, H1 2015 106
Number of Products under Development by Companies, H1 2015 (Contd..1) 107
Number of Products under Development by Companies, H1 2015 (Contd..2) 108
Number of Products under Development by Companies, H1 2015 (Contd..3) 109
Number of Products under Development by Companies, H1 2015 (Contd..4) 110
Number of Products under Development by Companies, H1 2015 (Contd..5) 111
Number of Products under Development by Companies, H1 2015 (Contd..6) 112
Number of Products under Development by Companies, H1 2015 (Contd..7) 113
Number of Products under Development by Companies, H1 2015 (Contd..8) 114
Number of Products under Development by Companies, H1 2015 (Contd..9) 115
Number of Products under Development by Companies, H1 2015 (Contd..10) 116
Number of Products under Development by Companies, H1 2015 (Contd..11) 117
Number of Products under Development by Companies, H1 2015 (Contd..12) 118
Number of Products under Development by Companies, H1 2015 (Contd..13) 119
Number of Products under Development by Companies, H1 2015 (Contd..14) 120
Number of Products under Development by Companies, H1 2015 (Contd..15) 121
Number of Products under Development by Companies, H1 2015 (Contd..16) 122
Number of Products under Development by Companies, H1 2015 (Contd..17) 123
Number of Products under Development by Companies, H1 2015 (Contd..18) 124
Number of Products under Development by Companies, H1 2015 (Contd..19) 125
Number of Products under Development by Companies, H1 2015 (Contd..20) 126
Number of Products under Development by Companies, H1 2015 (Contd..21) 127
Number of Products under Development by Companies, H1 2015 (Contd..22) 128
Number of Products under Development by Companies, H1 2015 (Contd..23) 129
Number of Products under Development by Companies, H1 2015 (Contd..24) 130
Number of Products under Development by Companies, H1 2015 (Contd..25) 131
Number of Products under Development by Companies, H1 2015 (Contd..26) 132
Number of Products under Development by Companies, H1 2015 (Contd..27) 133
Number of Products under Development by Companies, H1 2015 (Contd..28) 134
Number of Products under Development by Companies, H1 2015 (Contd..29) 135
Number of Products under Investigation by Universities/Institutes, H1 2015 137
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 140
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 141
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 142
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 143
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 144
Comparative Analysis by Late Stage Development, H1 2015 145
Comparative Analysis by Clinical Stage Development, H1 2015 146
Comparative Analysis by Early Stage Development, H1 2015 147
Comparative Analysis by Unknown Stage Development, H1 2015 148
Products under Development by Companies, H1 2015 149
Products under Development by Companies, H1 2015 (Contd..1) 150
Products under Development by Companies, H1 2015 (Contd..2) 151
Products under Development by Companies, H1 2015 (Contd..3) 152
Products under Development by Companies, H1 2015 (Contd..4) 153
Products under Development by Companies, H1 2015 (Contd..5) 154
Products under Development by Companies, H1 2015 (Contd..6) 155
Products under Development by Companies, H1 2015 (Contd..7) 156
Products under Development by Companies, H1 2015 (Contd..8) 157
Products under Development by Companies, H1 2015 (Contd..9) 158
Products under Development by Companies, H1 2015 (Contd..10) 159
Products under Development by Companies, H1 2015 (Contd..11) 160
Products under Development by Companies, H1 2015 (Contd..12) 161
Products under Development by Companies, H1 2015 (Contd..13) 162
Products under Development by Companies, H1 2015 (Contd..14) 163
Products under Development by Companies, H1 2015 (Contd..15) 164
Products under Development by Companies, H1 2015 (Contd..16) 165
Products under Development by Companies, H1 2015 (Contd..17) 166
Products under Development by Companies, H1 2015 (Contd..18) 167
Products under Development by Companies, H1 2015 (Contd..19) 168
Products under Development by Companies, H1 2015 (Contd..20) 169
Products under Development by Companies, H1 2015 (Contd..21) 170
Products under Development by Companies, H1 2015 (Contd..22) 171
Products under Development by Companies, H1 2015 (Contd..23) 172
Products under Development by Companies, H1 2015 (Contd..24) 173
Products under Development by Companies, H1 2015 (Contd..25) 174
Products under Development by Companies, H1 2015 (Contd..26) 175
Products under Development by Companies, H1 2015 (Contd..27) 176
Products under Development by Companies, H1 2015 (Contd..28) 177
Products under Development by Companies, H1 2015 (Contd..29) 178
Products under Development by Companies, H1 2015 (Contd..30) 179
Products under Development by Companies, H1 2015 (Contd..31) 180
Products under Development by Companies, H1 2015 (Contd..32) 181
Products under Development by Companies, H1 2015 (Contd..33) 182
Products under Development by Companies, H1 2015 (Contd..34) 183
Products under Development by Companies, H1 2015 (Contd..35) 184
Products under Development by Companies, H1 2015 (Contd..36) 185
Products under Development by Companies, H1 2015 (Contd..37) 186
Products under Development by Companies, H1 2015 (Contd..38) 187
Products under Development by Companies, H1 2015 (Contd..39) 188
Products under Development by Companies, H1 2015 (Contd..40) 189
Products under Development by Companies, H1 2015 (Contd..41) 190
Products under Development by Companies, H1 2015 (Contd..42) 191
Products under Development by Companies, H1 2015 (Contd..43) 192
Products under Development by Companies, H1 2015 (Contd..44) 193
Products under Development by Companies, H1 2015 (Contd..45) 194
Products under Development by Companies, H1 2015 (Contd..46) 195
Products under Investigation by Universities/Institutes, H1 2015 196
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 197
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 198
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 199
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 200
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 201
Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 202
Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 203
Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 204
Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 205
Products under Investigation by Universities/Institutes, H1 2015 (Contd..10) 206
Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2015 207
Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2015 208
Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 209
Breast Cancer - Pipeline by AB Science, H1 2015 210
Breast Cancer - Pipeline by AbbVie Inc., H1 2015 211
Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2015 212
Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 213
Breast Cancer - Pipeline by Adaptimmune Limited, H1 2015 214
Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015 215
Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 216
Breast Cancer - Pipeline by Advaxis, Inc., H1 2015 217
Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 218
Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2015 219
Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2015 220
Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 221
Breast Cancer - Pipeline by Affichem, H1 2015 222
Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2015 223
Breast Cancer - Pipeline by Alchemia Limited, H1 2015 224
Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 225
Breast Cancer - Pipeline by Almac Discovery Ltd., H1 2015 226
Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2015 227
Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015 228
Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015 229
Breast Cancer - Pipeline by Ambrx, Inc., H1 2015 230
Breast Cancer - Pipeline by Amgen Inc., H1 2015 231
Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 232
List Of Figures
List of Figures
Number of Products under Development for Breast Cancer, H1 2015 103
Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015 104
Number of Products under Development by Companies, H1 2015 105
Number of Products under Investigation by Universities/Institutes, H1 2015 136
Comparative Analysis by Late Stage Development, H1 2015 145
Comparative Analysis by Clinical Stage Development, H1 2015 146
Comparative Analysis by Early Stage Products, H1 2015 147
Assessment by Monotherapy Products, H1 2015 553
Assessment by Combination Products, H1 2015 554
Number of Products by Top 10 Targets, H1 2015 555
Number of Products by Stage and Top 10 Targets, H1 2015 555
Number of Products by Top 10 Mechanism of Actions, H1 2015 577
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 577
Number of Products by Top 10 Routes of Administration, H1 2015 591
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 591
Number of Products by Top 10 Molecule Types, H1 2015 593
Number of Products by Stage and Top 10 Molecule Types, H1 2015 593
